HC Wainwright Has Pessimistic View of Savara FY2026 Earnings

Savara Inc. (NASDAQ:SVRA) – HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Savara in a report issued on Monday, March 16th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.49) for the year, down from their previous estimate of ($0.39). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s FY2027 earnings at ($0.28) EPS and FY2028 earnings at $0.02 EPS.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

A number of other equities analysts have also weighed in on SVRA. Guggenheim reissued a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. William Blair set a $10.00 price target on shares of Savara in a report on Monday. UBS Group set a $10.00 price target on shares of Savara in a research note on Tuesday, December 23rd. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. Finally, Wells Fargo & Company increased their price objective on shares of Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Savara Trading Down 2.1%

Savara stock opened at $5.04 on Wednesday. Savara has a one year low of $1.89 and a one year high of $7.01. The business’s fifty day moving average is $5.64 and its 200 day moving average is $4.99. The stock has a market capitalization of $1.03 billion, a PE ratio of -9.51 and a beta of 0.31. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 7.65.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Osaic Holdings Inc. raised its stake in shares of Savara by 6.9% in the fourth quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock worth $197,000 after buying an additional 2,098 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Savara by 3.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock valued at $420,000 after acquiring an additional 2,116 shares during the period. Graham Capital Management L.P. grew its stake in shares of Savara by 4.9% during the 4th quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock valued at $338,000 after acquiring an additional 2,615 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Savara by 9.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock worth $200,000 after acquiring an additional 2,859 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after acquiring an additional 3,205 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Savara

Here are the key news stories impacting Savara this week:

• Positive Sentiment: Lifesci Capital nudged up near‑term forecasts — Q2 2026 EPS raised to ($0.12) from ($0.13) and FY2026 to ($0.48) from ($0.49). These marginal improvements signal slightly better expected near‑term performance. MarketBeat Savara Coverage
• Neutral Sentiment: HC Wainwright released detailed quarterly/near‑term model assumptions (Q1–Q4 2026 EPS estimates around ($0.13)–($0.09)) and reiterated a Buy rating — providing a full modeling framework investors can use but not a clear directional catalyst. MarketBeat Savara Coverage
• Negative Sentiment: HC Wainwright lowered FY2026 estimates (to ($0.49) from ($0.39)) and materially cut FY2027/FY2028 projections (FY2027 now ($0.28) vs prior ($0.16); FY2028 cut to $0.02 from $0.13), indicating the firm now models later profitability and/or slower commercial/clinical ramp than previously expected. MarketBeat Savara Coverage
• Negative Sentiment: HC Wainwright also trimmed longer‑term upside (FY2029 and FY2030 EPS reduced from prior forecasts), which lowers forward conviction and could pressure valuation until clearer clinical/commercial milestones arrive. MarketBeat Savara Coverage

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.